Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

BALTIMORE, May 21 /PRNewswire/ -- Alba Therapeutics Corporation announced today that data from its Phase IIa clinical trial were presented in the Clinical Advances in Celiac Disease session at the Digestive Disease Week (DDW) meeting in San Diego, California. Results of the randomized, double- blind, placebo controlled study of larazotide acetate for the prevention of celiac disease reactivation by gluten challenge in celiac subjects in remission(1) were presented by Daniel Leffler, MD from Beth Israel Deaconess Medical Center at the DDW today.

Celiac disease affects approximately 1% of individuals in the United States and Europe or approximately 6.5 million individuals. The only accepted therapy for the disease is a strict gluten-free diet; however, the response to therapy is poor or incomplete in up to 30% of patients. Dietary non-adherence is the chief cause of persistent or recurrent symptoms(2). Over time, 30-50% of individuals are unable to maintain a strict gluten-free diet. Additionally, a gluten-free diet fails to induce clinical or histological improvement in 7-30% of celiac patients and such a lack of response should trigger a systematic evaluation(3). These facts suggest that there is a need for therapeutic modalities beyond dietary modification.

Alba's study, the first Phase IIa trial in celiac disease and the first to assess dosing requirements for larazotide acetate, was designed to evaluate the safety, tolerability and efficacy of multiple doses of larazotide acetate in celiac disease subjects during a 2 week gluten challenge. The randomized, double-blind, placebo-controlled clinical trial enrolled 86 patients who had a confirmed biopsy diagnosis for celiac disease and were in compliance with a gluten-free diet for at least six months prior to enrollment as demonstrated by a negative serology test of anti-transglutaminase (tTG). Patients were randomized into seven drug-treated and placebo groups and challenged three times a day w
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...The Study Demonstrates microRNAs Extracted From a ...ffective Clinical Biomarkers for a Wide Range of ... Proprietary Technology, Rosetta Genomics is Curre...o Detect Colon Cancer, REHOVOT, Israel and JERSEY...ll/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a lea...
(Date:9/4/2008)...nother Roche first in TaqMan(R) real-time PCR test... lab, PLEASANTON, Calif., Sept. 4 /PRNewswir...s approved the Roche COBAS(R) TaqMan(R) HBV Test,... DNA approved in the U.S.,The test uses Roche,s re...epatitis B virus DNA in a patient,s blood. Doctors...
(Date:9/4/2008)...ivotal Study Seeks to Enroll 750 Women at More Tha...4 /- QuatRx Pharmaceuticals, a,privat...lopment and,commercialization of compounds to trea...s, today announced that it has initiated a second,...ablets), the company,s,estrogen-free oral therapy ...
(Date:9/4/2008)... Optimizing Patient Identification for Ta... of Personalized Treatment HUNTINGTON BEACH, Ca...ire/ -- Agendia, a world leader in molecular cance...tPrint(R), a new diagnostic test that,allows physi...ion levels of,the estrogen receptor (ER), progeste...
Breaking Medicine Technology:Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Agendia Launches TargetPrint(R) for Breast Cancer Patients 2DiObex and Camurus Sign License Agreement for the Development of DIO 901 in FluidCrystal 28R 29 Extended Release Technology 4031 1DiObex and Camurus Sign License Agreement for the Development of DIO 901 in FluidCrystal 28R 29 Extended Release Technology 4031 2Jazz Pharmaceuticals Inc Announces Expansion of Senior Debt 4030 1Jazz Pharmaceuticals Inc Announces Expansion of Senior Debt 4030 2Misys and Allscripts Create a Leader in Healthcare Software 4027 1Reducing HD risk naturally post menopause 14530 1Reducing HD risk naturally post menopause 14530 2
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...n epilepsy drug would help alcoholics quit drinkin... more than 50% of the alcoholics who took Topirama... sharply. In comparison with the placebo treatment...ly to abstain from drinking. It is believed that t...
...say an experimental drug developed to treat the co...spiratory Syndrome (SARS) virus. However they said...blic immediately. The drug is a relative of a reme...old are caused by the Corona virus, this could hel...
...l analysis from Australia says that older people t...ommitting suicide. However doctors feel that its n...amily doctors who by paying closer attention to pe...e has been an increasing role of general practitio...
...rown light on how brain processes disgusting image...who suffer from obsessive compulsive disorder (OCD...o fearful images. Fearful or disgusting images wer...based on their MRI scans. Scientists said that the...
Other Medicine News:
Features and Benefits: 1-12channel pipette This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-A
...ell plates in mind, Pipetman Ultra Multichannel is...tions: PCR* sequencing, immunology assays, series ...mond Tips from Gilson's patented Rocky Rack system...e productivity.,* PCR process is covered by US pat...
...ion, ergonomics, and value!, Comfortable feel and...andle , Finer control while pipetting with smooth,...ction with long, lever tip ejector , Completely au...ion without the need for recalibration , Easy-to-r...
Finnpipette Focus multichannel pipettes speed up repeat dispensing of reagents into microplates, with super blow-out for 0.1-10 l volumes. The improved ergonomic design of Finnpipette Focus multichan
Medicine Products: